Sugi Predict

Sugi Predict / Compounds / SCHEMBL451444

SCHEMBL451444

SCHEMBL451444

CC1(C)OB(c2cnc3sccc3c2)OC1(C)C

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ LPL P06858 11/20 0.40
▸ LIPG Q9Y5X9 11/20 0.40
▸ PDGFRB P09619 3/20 0.38
▸ KDR P35968 3/20 0.38
▸ ALPL P05186 1/20 0.37
▸ DGAT1 O75907 1/20 0.36
▸ AAK1 Q2M2I8 1/20 0.36
▸ CA12 O43570 1/20 0.34
▸ CA1 P00915 1/20 0.34
▸ CA2 P00918 1/20 0.34
▸ CA3 P07451 1/20 0.34
▸ CA4 P22748 1/20 0.34
▸ CA6 P23280 1/20 0.34
▸ CA5A P35218 1/20 0.34
▸ CA7 P43166 1/20 0.34
▸ CA9 Q16790 1/20 0.34
▸ CA14 Q9ULX7 1/20 0.34
▸ CA5B Q9Y2D0 1/20 0.34
▸ SNCA P37840 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL583512 0.76 LPL (0.40) LPLLIPGPDGFRBKDRALPL
SCHEMBL451893 0.74 LPL (0.47) LPLLIPGCA12CA1CA2
SCHEMBL30620315 0.74 LPL (0.47) LPLLIPGCA12CA1CA2
SCHEMBL15579103 0.74 AAK1 (0.36) LPLLIPGPDGFRBKDRALPL
SCHEMBL167417 0.72 ALPL (0.57) LPLLIPGPDGFRBKDRALPL
SCHEMBL30322634 0.72 SNCA (0.36) LPLLIPGPDGFRBKDRALPL
SCHEMBL584307 0.71 LPL (0.40) LPLLIPGPDGFRBKDRALPL
SCHEMBL14727556 0.70 LPL (0.46) LPLLIPGCA12CA1CA2
SCHEMBL31221823 0.70 LPL (0.43) LPLLIPGPDGFRBKDRALPL
SCHEMBL12127201 0.70 LPL (0.43) LPLLIPGPDGFRBKDRALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12448392-B2 Spiropiperidine derivatives CEPHALON LLC (US) 2025-10-21 — — US disclosed
US-20240166661-A1 Spiropiperidine Derivatives CEPHALON LLC 2024-05-23 — — US disclosed
US-11878982-B2 Spiropiperidine derivatives 89BIO LTD (IL) 2024-01-23 — — US disclosed
US-20210284651-A1 Spiropiperidine Derivatives CEPHALON LLC 2021-09-16 — — US disclosed
US-11046707-B2 Spiropiperidine derivatives 89BIO LTD (IL) 2021-06-29 — — US disclosed
US-20200031840-A1 SPIROPIPERIDINE DERIVATIVES CEPHALON LLC 2020-01-30 — — US disclosed
EP-3554637-A1 SPIROPIPERIDINE DERIVATIVES 89Bio Ltd. (IL) 2019-10-23 — — EP disclosed
WO-2018112204-A1 SPIROPIPERIDINE DERIVATIVES CEPHALON, INC. (US) 2018-06-21 — — WO disclosed
US-8591943-B2 Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors MERCK SHARP & DOHME CORP. (US) 2013-11-26 — — US disclosed
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 — — US disclosed
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 — — US disclosed
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 — — US disclosed
US-20120065219-A1 SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE ABBOTT LABORATORIES (US) 2012-03-15 — — US disclosed
EP-2417138-A1 PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS Schering Corporation (US) 2012-02-15 — — EP disclosed
US-8076350-B2 3H-(4's)-1'-azaspiro[benzofuran-2,4']-tricyclo[3.3.1.13,7]decane; for therapy of memory disorder, cognitive disorder, neurodegeneration, and neurodevelopmental disorder; attention deficit disorder, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment ABBOTT LABORATORIES (US) 2011-12-13 — — US disclosed
WO-2010118207-A1 PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS SCHERING CORPORATION (US) 2010-10-14 — — WO disclosed
US-20080153860-A1 SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE ABBOTT LABORATORIES (US) 2008-06-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065219-A1 SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE NR3C2, REN, GNE LPL 3721/4885LIPG 2614/4885PDGFRB 685/4885
US-20080153860-A1 SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE NR3C2, REN, GNE LPL 3773/4885LIPG 2767/4885PDGFRB 744/4885
US-11878982-B2 Spiropiperidine derivatives FASN, FADS2, SCD5 LPL 130/4885LIPG 306/4885PDGFRB 2530/4885
US-20210284651-A1 Spiropiperidine Derivatives FASN, FADS2, SCD5 LPL 130/4885LIPG 306/4885PDGFRB 2530/4885
US-20200031840-A1 SPIROPIPERIDINE DERIVATIVES FASN, FADS2, SCD5 LPL 130/4885LIPG 306/4885PDGFRB 2530/4885
US-12448392-B2 Spiropiperidine derivatives FASN, FADS2, SCD5 LPL 130/4885LIPG 306/4885PDGFRB 2530/4885
US-20240166661-A1 Spiropiperidine Derivatives FASN, FADS2, SCD5 LPL 130/4885LIPG 306/4885PDGFRB 2530/4885
US-11046707-B2 Spiropiperidine derivatives FASN, FADS2, SCD5 LPL 130/4885LIPG 306/4885PDGFRB 2530/4885
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MTOR, RICTOR, RPTOR LPL 3889/4885LIPG 3698/4885PDGFRB 1268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.